Clinical trial · Observational
Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer
The Role of Bladder Cancer TAS2R38 Expression on Chemotherapy-Induced Bitter Taste
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Alteration in the sense of taste is a frequent symptom that is closely linked to chemotherapy exposure, lowering quality of life and nutritional status. Malnutrition is of particular concern in muscle-invasive bladder cancer (MIBC), as malnutrition is associated with many negative outcomes from radical cystectomy (the surgical procedure in MIBC), which include higher morbidity, poor wound healing, and higher rate of infections after surgery. It is essential to understand taste changes among participants receiving chemotherapy for MIBC to create future treatment trials.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Changes in Taste Perception After Exposure to Chemotherapy
- description
- A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
Primary outcomes (1)
- measure
- Perceived strength of taste for the bitter and sweet tastes
- timeFrame
- From baseline (0-14 days prior to initial chemotherapy) until day of surgery (prior to participant undergoing surgery)
- description
- Taste solution testing using Spectrum(TM) Descriptive Analysis Method. Taste perception is measured on an ordinal scale (e.g. Moderate, Strong, Very Strong).
Secondary outcomes (6)
- measure
- Changes in nutrition status
- timeFrame
- 0-14 days prior to initial chemotherapy until (before) day of surgery
- description
- Patient-Generated Subjective Global Assessment (PG-SGA).The PG-SGA Short Form consist of four questions for the participant to rate their weight, food intake, any symptoms they are experiencing and their activity level, with each answer having a numerical correspondence. That score will be combined with the providers health assessment of weight loss, other health conditions that could affect nutrition, any present symptoms and physical exam; again each evaluation will be given a numeric value. The combined scores will determine the participants level of health; with A being well nourished, B being moderate/ suspected malnourished and C being severely malnourished.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent. * Age ≥ 18 years. * Histologically proven MIBC (Muscle Invasive Bladder Cancer) without metastatic disease Diagnosis. * Planning to undergo neoadjuvant chemotherapy and radical cystectomy for MIBC Exclusion Criteria: * No prior systemic chemotherapy for MIBC. * Cannot be simultaneously enrolled in any therapeutic clinical trial, unless receiving standard neoadjuvant chemotherapy on said clinical trial. * Any oral or cognitive pathology impairing the ability to perform taste testing procedures. * No other known malignancy within previous 2 years with the following EXCEPTIONS: Low-grade prostate cancer on active surveillance, CLL on surveillance / observation, non-melanoma skin cancers. * No psychiatric illness/social situations that would limit compliance with study requirements.
References
Publications (0)
Data not yet available